Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diva LaboratoriesROCO:4153 +0.48%74 Gross Margin % is 31.68% as of Dec. 2025, which is 10% above its 10-year median of 28.74. GuruFocus rates ROCO:4153 with a GF Score™ of 74/100 and a GF Value™ of NT$38.03 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Diva Laboratories ranks worse than 74.74% on this metric.
The historical rank and industry rank for Diva Laboratories's Gross Margin % or its related term are showing as below:
ROCO:4153'
s Gross Margin % Range Over the Past 10 Years
Min: 21.21 Med: 28.74 Max: 31.48
Current: 30.4
During the past 13 years, the highestGross Margin % of Diva Laboratories was 31.48%. The lowest was 21.21%. And the median was 28.74%.
ROCO:4153's Gross Margin % is ranked worse than 74.74% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 51.14
vs ROCO:4153: 30.40
Diva Laboratories had a gross margin of 31.68% for the quarter that ended in Dec. 2025 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Diva Laboratories was 2.10% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Diva Laboratories had a gross margin of 31.68% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Diva Laboratories Gross Margin % Related Terms
Diva Laboratories Gross Margin % Historical Data
* Premium members only.
The historical data trend for Diva Laboratories's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4153 vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Diva Laboratories's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diva Laboratories Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diva Laboratories's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Diva Laboratories's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Diva Laboratories (ROCO:4153) has a Gross Margin % of 31.68% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Diva Laboratories and its competitors. This is 10% above median its historical median of 28.74. Over the past decade, Diva Laboratories' Gross Margin % has ranged from 21.21 to 31.48. According to the industry distribution chart, Diva Laboratories ranks #145 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 74.7%.
Is Diva Laboratories' Gross Margin % too high?
Diva Laboratories' current Gross Margin % of 31.68% is 10% above median its 10-year median of 28.74. Over the past 10 years, this metric has ranged from a low of 21.21 to a high of 31.48. The Medical Diagnostics & Research industry median Gross Margin % is 51.14. Diva Laboratories' value of 31.68% is 38.1% below this industry median. Based on the distribution chart, Diva Laboratories ranks #145 out of 194 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Diva Laboratories has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diva Laboratories' Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diva Laboratories ranks #145 out of 194 companies for Gross Margin %. This places Diva Laboratories in the lower half of its industry. The industry median Gross Margin % is 51.14. Diva Laboratories' value of 31.68% is 38.1% below this benchmark. Historically, Diva Laboratories' own Gross Margin % has ranged from 21.21 to 31.48 over the past decade. While the company's 10-year median is 28.74 vs. the industry median of 51.14, Diva Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 51.14, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diva Laboratories's current Gross Margin % of 31.68% is 38.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Diva Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 51.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diva Laboratories's current Gross Margin % is 31.68%, which is 10% above median its own 10-year median of 28.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diva Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Diva Laboratories (ROCO:4153) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$38.03, compared to a current price of NT$31.40 — trading 17.4% below its estimated fair value. The current Gross Margin % is 31.68%, which is 10% above median its 10-year median of 28.74 and 38.1% below the Medical Diagnostics & Research industry median of 51.14. Diva Laboratories' overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Diva Laboratories (ROCO:4153), the current Gross Margin % is 31.68% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diva Laboratories (ROCO:4153) Overvalued in 2026?
Based on GuruFocus' analysis, Diva Laboratories stock appears to be undervalued.
The current stock price of NT$31.40 is trading 17.4% below its estimated GF Value™ of NT$38.03.
GuruFocus considers Diva Laboratories to be Modestly Undervalued.
Key valuation signals for ROCO:4153:
Gross Margin %: 31.68% (10% above median its 10-year median of 28.74)
GF Value™: NT$38.03 vs. price of NT$31.40 (17.4% below fair value)
Industry Position: 38.1% below the Medical Diagnostics & Research median (#145 of 194)
No single metric tells the full story. See the ROCO:4153 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diva Laboratories Ltd is engaged in the sale, manufacturing and development of medical equipment and computer-related devices. Its products are divided into Medical display which includes radiology, endo/surgical, touch, and embedded display; and Industrial display which includes touch display monitors. It derives revenue from sale of Medical monitors, Medical parts, Industrial monitors, Industrial parts, and Parts. Geographically it operates and derives revenue from Taiwan.
74GF Score
Get the complete analysis for ROCO:4153
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4153 has been successfully added to your 
